Grounds For Patent Revocation.
1. Patent Revocation
Patent revocation means the legal cancellation of a granted patent, either fully or partially. Once revoked, the patent ceases to exist, and the invention falls into the public domain.
Under the Patents Act, 1970 (as amended in 2005), revocation can occur through:
Central Government / Controller of Patents
High Court / IPAB (Intellectual Property Appellate Board)
Who Can File for Revocation?
Any person interested – competitors, licensees, or public.
Central Government – for public interest, health, or defense.
Controller of Patents – during post-grant opposition or litigation.
2. Grounds for Patent Revocation
A. Lack of Novelty (Section 64(1)(a))
The invention is already known in India or abroad before the priority date.
Example: Prior publication in journals, patents, or public use.
B. Obviousness / Lack of Inventive Step (Section 64(1)(b))
The invention is obvious to a person skilled in the art.
It does not involve a significant innovation beyond prior art.
C. Non-Patentable Subject Matter (Section 64(1)(c) & 3)
Inventions excluded from patentability:
Section 3(d): Mere new form of known substance without efficacy.
Section 3(j): Plants and animals other than microorganisms, essentially biological processes.
Section 3(h): Traditional knowledge.
D. Inadequate Disclosure (Section 64(1)(d))
The patent does not fully disclose the invention to allow a skilled person to reproduce it.
Lack of clarity, enabling disclosure, or omission of key technical data.
E. Wrongful Acquisition (Section 64(1)(e))
The patent was wrongly obtained, e.g., by misrepresentation, fraud, or concealing prior art.
F. Non-Working of Patent (Section 85)
If a patented invention is not worked in India or the public is deprived of its benefits.
Often invoked in compulsory licensing disputes.
3. Landmark Cases on Patent Revocation
Case 1: Novartis AG v. Union of India (2013)
Facts:
Novartis applied for patent on the cancer drug Glivec, a beta crystalline form of imatinib. Opponents claimed it lacked novelty and efficacy.
Decision:
Supreme Court rejected the patent under Section 3(d).
It held that the new form of a known substance did not show enhanced efficacy, hence not patentable.
Significance:
Clarified stringent standards for patentability in pharmaceuticals.
Highlighted ground of non-patentable subject matter as a key basis for revocation.
Case 2: Bayer Corporation v. Natco Pharma (2012)
Facts:
Bayer’s patented cancer drug faced challenge for non-working in India.
Decision:
Controller recognized compulsory licensing due to public health needs.
Revocation was not total, but working requirements were enforced.
Significance:
Non-working of patent can lead to government intervention or revocation-like effects.
Case 3: Roche Products Ltd. v. Cipla Ltd. (2014)
Facts:
Roche challenged Cipla’s production of generic versions. Cipla claimed patent lacked novelty in India.
Decision:
Courts examined prior art and public disclosures, reaffirming the need for novelty.
Revocation grounds under Section 64(1)(a) and (b) were applied.
Significance:
Reinforces novelty and inventive step as key grounds for revocation.
Case 4: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2016)
Facts:
Monsanto patented Bt cotton seeds. Nuziveedu challenged on non-disclosure and working issues.
Decision:
Court ruled Monsanto's patent valid, but farmers’ rights and working conditions were enforced.
Demonstrated partial revocation or limitation is possible.
Significance:
Highlights working and disclosure as actionable grounds for revocation.
Case 5: F. Hoffmann-La Roche Ltd. v. Cipla (2010)
Facts:
Patent for an anti-cancer drug challenged on the ground of obviousness and prior art.
Decision:
Tribunal found lack of inventive step; patent partially revoked.
Key principle: mere routine improvement is not patentable.
Significance:
Inventive step is central to revocation challenges.
Case 6: Wockhardt v. Natco Pharma (2012)
Facts:
Wockhardt’s patented formulation of antibiotic challenged for inadequate disclosure.
Decision:
Tribunal revoked the patent because a skilled person could not reproduce the invention.
Demonstrates the importance of full specification and enablement.
Significance:
Shows inadequate disclosure as a strong ground for revocation.
Case 7: Syngenta Seeds v. Controller of Patents (2015)
Facts:
Patent on genetically modified seed challenged for non-patentable subject matter (plant variety exclusion).
Decision:
Patent revoked under Section 3(j).
Reinforced exclusion of plants and essentially biological processes.
Significance:
Confirms Indian law strictly prohibits patenting of certain biological inventions.
4. Key Takeaways
Most common grounds for revocation: lack of novelty, inventive step, and non-patentable subject matter.
Disclosure is critical: vague or incomplete specification invites revocation.
Public interest / working requirements can trigger revocation-like interventions.
Partial or limited revocation is possible; courts may restrict rights rather than cancel the patent entirely.
Indian courts maintain strict standards for pharmaceutical and biotech patents under Sections 3(d), 3(j), and 64.
RELATED Blog
comments